Navigation Links
ViewRay Closes Round of Series C Financing
Date:3/14/2012

CLEVELAND, March 13, 2012 /PRNewswire/ -- ViewRay™ Incorporated, a privately held medical device company, has closed the final tranche of a $45 million round of Series C venture capital financing. Institutional investors include Aisling Capital, Fidelity Biosciences, Kearny Venture Partners, OrbiMed Advisors and Siemens Venture Capital (SVC) GmbH.

The ViewRay system is designed as the first comprehensive image-guided radiation therapy system, providing a patented combination of simultaneous radiotherapy delivery and continuous magnetic resonance imaging (MRI) for the treatment of cancer. ViewRay's treatment planning and delivery software received 510(k) premarket notification clearance from the U.S. FDA in 2011, and its integrated imaging and radiotherapy delivery system is now pending 510(k) review.

"Thanks to the ongoing commitment of our investors, ViewRay is in the process of preparing for market launch," said ViewRay President and CEO Gregory M. Ayers, MD, PhD. "With our continued and substantial progress, our investors are even more enthusiastic about the potential of ViewRay and the promise of MRI-guided radiotherapy."

The first ViewRay research system is undergoing final installation at the Siteman Cancer Center at Barnes‐Jewish Hospital and Washington University School of Medicine in St. Louis, Missouri. Additional ViewRay research partners include the University of Wisconsin Carbone Cancer Center and the University of California, Los Angeles, Health System and Jonsson Comprehensive Cancer Center.

About ViewRay

ViewRay Incorporated of Cleveland, Ohio, is a privately held medical device company developing advanced radiation therapy technology for the treatment of cancer. The ViewRay system is being designed to provide continuous soft-tissue imaging during treatment, using MRI-guided radiotherapy, so that clinicians will be able to see where the actual radiation dose is being delivered and adapt to changes in the patient's anatomy. For more information, visit http://www.viewray.com.

ViewRay is a trademark of ViewRay Incorporated.

ViewRay acknowledges the contribution of the State of Ohio, Department of Development and Third Frontier Commission, which provided funding in support of the MRI Technology Enabling Expansion of MRI into Radiotherapy Guidance Project.


'/>"/>
SOURCE ViewRay
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ViewRay Demonstrates Potential Therapy Applications for MRI-Guided Radiation at ASTRO 2011
2. UCLA Health System - Jonsson Comprehensive Cancer Center to Acquire ViewRay Radiation Therapy Research System
3. Landmark Patents Issued for ViewRay Technology
4. University of Wisconsin Carbone Cancer Center to Acquire ViewRay Radiation Therapy System
5. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
6. ViewRay Secures Series C Financing
7. Siteman Cancer Center at Barnes-Jewish and Washington University to Receive First ViewRay Radiation Therapy System
8. ViewRay Wins NorTech Innovation Award
9. Cayenne Medical Closes $10 Million Capital Raise
10. Insero Health Closes Initial Round of Financing and Signs Exclusive Licenses With Harvard and Yale
11. Aethlon Medical Discloses Availability of the Biotech Showcase™ 2012 Presentation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2017)... , Aug. 2, 2017 ... Who,s Who as a Pinnacle Lifetime Professional in ... Key Account Manager at Turing Pharmaceuticals, AG. Her ... troubleshooting and relationship building.                ... more than 25 years of experience as a ...
(Date:8/1/2017)... 2017   CerSci Therapeutics , a non-opioid drug ... , has received notice from the National Institute on ... (NIH) that it has been awarded a Direct-to-Phase II ... in 2017 with an additional $1,000,000 to follow in ... application of their lead non-opioid drug candidate CT-044 to ...
(Date:7/28/2017)... July 28, 2017 Hill-Rom Holdings, Inc. ("Hill-Rom") ... third quarter ended June 30, 2017, and updated its ... For the fiscal third quarter, Hill-Rom ... $0.68 per diluted share in the prior-year period. These ... $0.39 per diluted share primarily related to the non-cash ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... 2017 , ... An August 3rd article on Reuters covers a new University of ... JAMA (the Journal of the American Medical Association). The study found that a lower percentage ... 30, when compared to patients with lower BMIs. At present, weight loss patients must have ...
(Date:8/16/2017)... ... August 16, 2017 , ... The Data Council, the leading ... was acquired by Advantage Solutions. The Data Council’s IX-ONE platform is the ... industry’s leading suppliers, brokers, distributors and retailers. The Data Council will become a ...
(Date:8/16/2017)... ... August 16, 2017 , ... In ... They celebrate 30 years in business this year, and they’re marking the milestone ... space to serve their patients. , It stands to reason that, given ...
(Date:8/16/2017)... ... August 16, 2017 , ... Modern Consulting Insurance & ... program. Partnering once again with Boys & Girls Clubs of Greater Kansas City, ... area’s very own American Idol. With all proceeds benefitting local worthy causes, donations ...
(Date:8/16/2017)... ... ... Paul Vitenas, MD, FACS , is honored to announce that he ... the nation’s top physicians, in a variety of specialties. This marks the fourth year ... Connolly’s coveted ranking. , Castle Connolly is the nation’s trusted provider of information on ...
Breaking Medicine News(10 mins):